MedTrace Logo

RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS

NCT03979456 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-04-19

No results posted yet for this study

Summary

A randomized trial of long-term dosage of rituximab in multiple sclerosis

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Rituximab

After one year in the trial, the patients are split in the two dosing-arms described above. The dose-comparison phase continues four years.

Sponsors & Collaborators

Principal Investigators

  • Anders Svenningsson, Professor · Dept of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
52 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-04
Primary Completion
2024-12-20
Completion
2025-06-01

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03979456 on ClinicalTrials.gov